KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Cash & Current Investments: 2010-2025

Historic Cash & Current Investments for Emergent BioSolutions (EBS) over the last 15 years, with Sep 2025 value amounting to $249.2 million.

  • Emergent BioSolutions' Cash & Current Investments rose 59.34% to $249.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $778.6 million, marking a year-over-year increase of 86.22%. This contributed to the annual value of $105.6 million for FY2024, which is 5.46% down from last year.
  • Latest data reveals that Emergent BioSolutions reported Cash & Current Investments of $249.2 million as of Q3 2025, which was down 8.04% from $271.0 million recorded in Q2 2025.
  • Emergent BioSolutions' 5-year Cash & Current Investments high stood at $642.6 million for Q4 2022, and its period low was $71.0 million during Q2 2024.
  • Its 3-year average for Cash & Current Investments is $163.9 million, with a median of $111.7 million in 2023.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first plummeted by 82.62% in 2023, then spiked by 281.69% in 2025.
  • Over the past 5 years, Emergent BioSolutions' Cash & Current Investments (Quarterly) stood at $576.3 million in 2021, then climbed by 11.50% to $642.6 million in 2022, then crashed by 82.62% to $111.7 million in 2023, then dropped by 5.46% to $105.6 million in 2024, then skyrocketed by 59.34% to $249.2 million in 2025.
  • Its Cash & Current Investments stands at $249.2 million for Q3 2025, versus $271.0 million for Q2 2025 and $152.8 million for Q1 2025.